CareDx Partners with TC BioPharm to Advance Hematology Oncology Treatments

Strategic Partnership Enhances CareDx's Role in Hematology Oncology

CareDx, Inc., a prominent precision medicine company based in Brisbane, California, has forged a significant strategic partnership with TC BioPharm to employ its AlloCell™ solution in the ACHIEVE clinical trial. This adaptive, open-label, phase II study is focused on evaluating TCB008, an allogeneic gamma-delta T-cell therapy aimed at patients diagnosed with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). The collaboration underscores CareDx’s ambition to extend its footprint in the hematology oncology sector, where innovative treatments are critical for improving patient outcomes.

The AlloCell solution has been previously utilized in ten clinical trials and will now play an integral role in four active studies, including the ACHIEVE trial. Marica Grskovic, Chief Strategy Officer at CareDx, highlights the importance of pharmacokinetic monitoring in this context, facilitating a deeper understanding of TCB008's performance within trial participants. By leveraging the AlloCell test, researchers can gather essential data regarding the expansion and persistence of gamma-delta T-cells, which are pivotal in reconstituting the immune system of AML patients. This information is crucial for assessing both the efficacy and effectiveness of TCB008, contributing to a more nuanced approach to treating these complex conditions.

The collaboration signifies a proactive approach to advancing treatment modalities in hematological cancers. Alison Bracchi, Executive Vice President of Clinical Operations at TC BioPharm, notes that this partnership is vital for the development of TCB008 as a viable therapy for blood cancers. CareDx’s commitment to delivering high-value healthcare solutions and genomics-based information positions the company as a key player in the evolving landscape of precision medicine, particularly for transplant patients. As they integrate their expertise with TC BioPharm’s innovative therapies, CareDx takes a significant step forward in enhancing treatment options for patients facing challenging diagnoses like AML and MDS.

In addition to this partnership, CareDx remains dedicated to providing comprehensive testing services that support patients throughout their transplant journeys. This focus on high-value healthcare solutions not only reinforces their leadership in the field but also demonstrates a commitment to improving patient care through innovation and collaboration. The ongoing efforts in the ACHIEVE trial signify a forward-looking approach that aims to reshape treatment paradigms in hematology oncology. For further information about CareDx’s expanding portfolio and initiatives, visit www.caredx.com.